CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation (CACAF-2)

Biosense Webster

Status and phase

Terminated

Phase 4

Conditions

Atrial Fibrillation

Treatments

Device: RF ablation

Drug: Antiarrhythmic drugs

Study type

Interventional

Funder types

Industry

Identifiers

NCT00227344

CACAF2

Details and patient eligibility

About

The objective of this prospective multicenter randomized study is to establish the effectiveness of treatment of persistent atrial fibrillation by encircling the pulmonary veins with radiofrequency (RF) ablation and creating additional lines of block with the aid of the NAVISTAR® THERMOCOOL® catheter in conjunction with the CARTO™ EP Navigation System. Effectiveness will be determined by comparing the chronic success of ablation therapy versus antiarrhythmic drug therapy, defined as the absence of persistent tachyarrhythmias during the first 24 months after a run-in phase of 2 months.

Enrollment

129 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18-70 years
Written informed consent
One documented relapse of atrial fibrillation (AF) during antiarrhythmic drug therapy after an electrical cardioversion

Exclusion criteria

Permanent atrial fibrillation
Patients who had tried >1 antiarrhythmic drug (Class I or Class III).
AF was the sole rhythm for >6 months before the enrollment.
Previous ablation for AF.
AF is deemed secondary to a transient or correctable abnormality including electrolyte imbalance, trauma, recent surgery, infection, toxic ingestion, and endocrinopathy.
Patients who have fibrillation episodes triggered by another uniform arrhythmia (eg, atrial flutter or atrial tachycardia).
Patients with intra-atrial thrombus, tumor, or another abnormality that precludes catheter introduction.
Patients with Wolf-Parkinson-White syndrome.
Patients awaiting cardiac transplantation.
Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-III-IV or ejection fraction (EF) <40%.
Patients with unstable angina or acute myocardial infarction within 3 months.
Patients with cardiac revascularization or other cardiac surgery within 6 months.
Patients with heart disease in which corrective surgery is anticipated.
Patients in whom appropriate vascular access is precluded.
Pregnant women.
A separate requirement for antiarrhythmic drug treatment, which will require an antiarrhythmic drug not previously tried for AF suppression.
Prior atrial surgery.
Contraindication to treatment with warfarin or other bleeding diathesis.
Renal failure requiring dialysis.
Hepatic failure.
Participant in investigational clinical or device trial.
Unwilling or unable to give informed consent.
Inaccessible for follow-up.
Psychological problem that might limit compliance.
Active abuse of alcohol or other drugs which may be causative of AF.
An implanted device (pacemaker or cardioverter-defibrillator).
Left atrial diameter (anteroposterior) >50 mm.